Repatha's Cardiovascular Benefits Are Driving Labelling Changes

You'll get questions about Repatha to reduce risk of CV events.

This PCSK9 inhibitor is now approved for patients with CV disease to reduce the risk of CV events.

This is a case of labelling catching up with the evidence.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote